6-hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata.,British Journal of Pharmacology

当前位置： X-MOL 学术 › Br. J. Pharmacol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

6-hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata.
British Journal of Pharmacology ( IF 6.8 ) Pub Date : 2020-05-28 , DOI: 10.1111/bph.15145
Sergio Vegas-Suárez _{1,

2} , Clarissa Anna Pisanò _{3,

4} , Catalina Requejo ₅ , Harkaitz Bengoetxea ₅ , Jose Vicente Lafuente ₅ , Michele Morari _{3,

4} , Cristina Miguelez _{1,

2} , Luisa Ugedo _{1,

2}

Affiliation

l‐DOPA‐induced dyskinesia (LID) is considered a major complication in the treatment of Parkinson's disease (PD). Buspirone (5‐HT_1A partial agonist) have shown promising results in the treatment of PD and LID, however no 5‐HT‐based treatment has been approved in PD. The present study was aimed to investigate how the substantia nigra pars reticulata (SNr) is affected by buspirone and whether it is a good target to study 5‐HT antidyskinetic treatments.

中文翻译：

6-羟基多巴胺损伤和左旋多巴治疗改变了丁螺环酮在黑质网状部的作用。

l -DOPA引起的运动障碍（LID）被认为是帕金森病（PD）治疗的主要并发症。丁螺环酮（5-HT _1A部分激动剂）在 PD 和 LID 的治疗中显示出有希望的结果，但尚未批准基于 5-HT 的 PD 治疗。本研究旨在探讨丁螺环酮如何影响黑质网状部(SNr)，以及它是否是研究 5-HT 抗运动障碍治疗的良好靶点。

更新日期：2020-05-28

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11